Abstracts tagged "Crystal-induced arthritis"

Abstract Number: 1139 • ACR Convergence 2025
Synovial Counts, Cultures, and Crystals: An Analysis of 9,000 Aspirations
Sabahat Usmani¹, Gunjan Rana², Shivum Patel¹, Patrick Kennedy¹ and Michael Putman³, ¹Medical College of Wisconsin, Milwaukee, ²Saint Vincent Hospital, Worcester, MA, ³The Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Synovial fluid analysis is an essential diagnostic tool for evaluating crystalline and infectious arthritis. Traditionally, a leukocyte count threshold of >50,000 cells/µL has been…
Abstract Number: 1138 • ACR Convergence 2025
Efficacy of Pozdeutinurad (AR882) in Treatment Naïve and Suboptimally Treated Gouty Arthritis with Tophi
Robert Keenan¹, Puja Khanna², Zancong Shen³, Sarah Morris³, Pamela Mundell⁴, Wen Wei⁴, Elizabeth Polvent⁵, Vijay Hingorani⁶, Shunqi Yan⁵ and Li-Tain Yeh⁷, ¹Arthrosi Therapeutics, Raleigh, NC, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³Arthrosi therapeutics, San Diego, CA, ⁴Arthrosi Therapeutics Inc, San Diego, CA, ⁵Arthrosi Therapeutics, Inc., San Diego, CA, ⁶Vanguard Healthsciences, Inc., San Diego, CA, ⁷Arthrosi Therapeutics, Inc., Irvine, CA
Background/Purpose: Pozdeutinurad (AR882, POZD) is a novel, selective URAT1 inhibitor currently in phase 3 clinical stage development for the treatment of gout and tophaceous gout.…
Abstract Number: 1136 • ACR Convergence 2025
The Impact of Iron Overload and HFE Genetic Mutations on Joint Disease in Haemochromatosis: Data from the Haemochromatosis Arthropathy Inception Cohorts
Bayram Farisogullari¹, Pedro Machado², Stephanie Finzel³, Graeme Carroll⁴, Geraldine mcCarthy⁵, John Stack⁶, Simone Parisi⁷, Graca Porto⁸, richette pascal⁹, Gyorgy Nagy¹⁰, Marton Weidl¹⁰, Ann Rosenthal¹¹, Pascal Guggenbuhl¹², Katarzyna Banaszkiewicz¹³, Barbara Butzeck¹⁴, Howard Don¹⁵, Svenja Engelhardt¹⁶, Jeremy Shearman¹⁷, David Mitchell¹⁸, Jane Barker¹⁹, Valerie Brueton¹⁹, Philip Coathup¹⁹, Jacquie Dowsett¹⁹, Marie Duncan¹⁹, Tracey Dunleavy¹⁹, Ian Fish¹⁹, Allin Hoggarth¹⁹, Mark McKinnon¹⁹, James Minter¹⁹, Tim Osborne¹⁹, Marguerite Smith¹⁹, Christine Wright¹⁹ and Patrick Kiely²⁰, ¹University College London, London, ²Department of Rheumatology, University College London, and Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ³Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, ⁴Fiona Stanley Hospital, Perth, Western Australia, Australia, ⁵Mater Misericordiae University Hospital, Dublin, Ireland, ⁶Mater Misericordiae University Hospital, Dublin, Dublin, Ireland, ⁷Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin, Italy, ⁸Centro Hospitalar Universitário de Santo António, Unidade Local de Saúde de Santo António, Porto, Portugal, ⁹Rheumatology Department, Lariboisiere Hospital, Paris, Ile-de-France, France, ¹⁰Buda Hospital of the Hospitaller Order of Saint John of God, Budapest, Hungary, ¹¹Department of Medicine, Division of Rheumatology, Medical College of Wisconsin, Wisconsin, ¹²Rennes University Hospital, Rennes, France, ¹³University Clinical Center in Gdańsk, Smoluchowskiego ¹⁷ Street, ⁸⁰-⁹⁵² Gdańsk, Poland., Gdańsk, Poland, ¹⁴European Federation of Associations of Patients with Haemochromatosis,, Croissy-sur-Seine, France, ¹⁵Haemochromatosis International, Barnstaple, United Kingdom, ¹⁶University of Freiburg, Freiburg im Breisgau, Germany, ¹⁷South Warwickshire University Foundation Trust and Warwick Medical School,, Warwick, United Kingdom, ¹⁸Clongriffin Medical Centre, Dublin, Ireland, ¹⁹c/o St George's University Hospitals NHS Trust, London, United Kingdom, ²⁰St George's University Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: A EULAR task force developed classification criteria (CC) for Haemochromatosis Arthropathy (HA) using a cohort of people with the C282Y homozygous mutation and arthropathy…
Abstract Number: 1135 • ACR Convergence 2025
A Gain-of-Function 5’UTR Variant in ANKH Causes Familial CPPD with Elevated Extracellular PPi and Citrate
richette pascal¹, christophe Duranton², Thomas Pinna³, Manon Ricquebourg⁴, LATOURTE Augustin⁵, Thomas Bardin⁶, Valérie Bousson⁷, Hang-Korng Ea⁸, Isabelle Rubera⁹ and Corinne Collet¹⁰, ¹Rheumatology Department, Lariboisiere Hospital, Paris, Ile-de-France, France, ²CNRS-UMR ⁷³⁷⁰ - Laboratoire de Physiomedecine moléculaire, Nice, Rhone-Alpes, France, ³INSERM U¹¹³², PARIS, Ile-de-France, France, ⁴Lariboisiere Hospital, INSERM U¹¹³², Paris, France, ⁵Rheumatology Department, Lariboisiere Hospital, Paris, France, ⁶Lariboisiere Hospital, Department of Rheumatology, Paris, France, ⁷Radiology Department, Lariboisiere Hospital, Paris, France, ⁸INSERM U¹¹³², Lariboisiere Hospital, Paris, France, ⁹CNRS-UMR ⁷³⁷⁰ - Laboratoire de Physiomedecine moléculaire, Nice, France, ¹⁰Reference Center for Skeletal Dysplasia, INSERM UMR ¹¹⁶³, Paris, France
Background/Purpose: To identify novel pathogenic variants associated with chondrocalcinosis (CC), we systematically screened individuals with a family history of CPPD using an NGS panel. Among…
Abstract Number: 1134 • ACR Convergence 2025
Efficacy and Safety of Anakinra for Acute Calcium Pyrophosphate Deposition Disease Flare: A Systematic Review and Meta-Analysis
Pannathorn Nakaphan¹, Somkiat Phutinart², Patavee Pajareya², Priabprat Jansem³, Nattanicha Chaisrimaneepan⁴, Pim Jetanalin⁵ and Noppachai Siranart², ¹Department of Internal Medicine, Weiss Memorial Hospital, Chicago, IL, ²Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, ³Department of Psychiatry, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand, ⁴Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, ⁵Department of Medicine, Division of Rheumatology, University of Illinois College of Medicine, Chicago, IL
Background/Purpose: Calcium Pyrophosphate Deposition Disease (CPPD) is a common inflammatory arthritis among older adults. Comorbidities often limit conventional treatment of acute CPPD flare. Anakinra, an…
Abstract Number: 1131 • ACR Convergence 2025
Variant Drives Tophus Formation through Dual Mechanisms: Extracellular Aggregation andvImpaired Macrophage Phagocytic Clearance
Yuqi wang¹, Lingjiang Zhu¹, Jinshuo Han², Junbin Qian³, Martin Herrmann⁴, Jing Xue¹ and Lei Liu¹, ¹The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China (People's Republic), ²Zhejiang University, School of Medicine, Hangzhou, China (People's Republic), ³Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China (People's Republic), ⁴University Hospital Erlangen, Erlangen, Germany
Background/Purpose: While aggregated neutrophil extracellular traps (aggNETs) constitute the primary structural component of tophi, the susceptible population for tophaceous gout remains poorly characterized. We investigated…
Abstract Number: 2588 • ACR Convergence 2025
Nanoencapsulated Sirolimus plus Pegadricase (NASP) Demonstrates a Reduction in Gout Flares: Results from the Phase 3 DISSOLVE Studies
Angelo Gaffo¹, Herbert Baraf², Anand Patel³, Tuhina Neogi⁴, Rehan Azeem⁵, Wesley DeHaan⁶, Ben Peace⁷, Hugues Santin-Janin⁸, Bhavisha Desai⁹ and Naomi Schlesinger¹⁰, ¹Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA, Birmingham, AL, ²The Center for Rheumatology and Bone Research, Rheumatology, Wheaton, Maryland, USA; Division of Rheumatology, The George Washington University, Washington, DC, ³Conquest Research, Winter Park, FL, USA, Winter Park, FL, ⁴Boston University School of Medicine, Boston, MA, ⁵Global MACD, Sobi Inc., Waltham, MA, ⁶Sobi, Inc, Waltham, MA, ⁷Statistical Science, Sobi, Stockholm, Sweden, ⁸Sobi, BASEL, Switzerland, ⁹Sobi, Glastonbury, CT, ¹⁰Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT, USA, Salt Lake City, UT
Background/Purpose: Urate-lowering therapy is recommended to lower serum urate (sUA) and for long-term prevention of gout flares (FitzGerald et al. Arthritis Care Res (Hoboken) 2020;…
Abstract Number: 1128 • ACR Convergence 2025
Association between leptin levels, body mass index and health-related quality of life in patients with gout
Inna Orlova¹, Iryna Shapoval², Nataliia Shkolina¹, Nataliia Kuzminova¹ and Mykola Stanislavchuk³, ¹National Pirogov Memorial Medical University, Vinnytsya, Vinnytsya, Ukraine, ²National Pirogov Memorial Medical University, Vinnytsya (Ukraine), Vinnytsya, Ukraine, ³National Pirogov Memorial Medical University, Vinnytsia, Vinnytsia, Ukraine
Background/Purpose: Gout is s a disease with a high disability rate, resulting in severe social burden and is associated with reduced health-related quality of life…
Abstract Number: 2587 • ACR Convergence 2025
Nanoencapsulated Sirolimus Plus Pegadricase Reduced Disease Burden in Patients With Uncontrolled Gout: Results From the Phase 3 DISSOLVE Trials
Puja Khanna¹, Amar Majjhoo², Rehan Azeem³, Ben Peace⁴, Bhavisha Desai⁵ and Vibeke Strand⁶, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Shores Rheumatology, St. Clair Shores, MI, ³Global MACD, Sobi Inc., Waltham, MA, ⁴Statistical Science, Sobi, Stockholm, Sweden, ⁵Sobi, Glastonbury, CT, ⁶Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: Patients (pts) with uncontrolled gout (UG; persistent elevation in serum uric acid [sUA] levels and clinical manifestations despite oral urate-lowering therapy) have poor health-related…
Abstract Number: 1126 • ACR Convergence 2025
Clinical Impact of Signs of Calcium Pyrophosphate Deposition Disease (CPPD) on Radiographs of Hands and Wrists in a Real-World Cohort of Patients with Early Rheumatoid Arthritis
Coralie Tremblay¹, Nathalie Carrier², Hugues Allard-Chamard³, Javier Marrugo⁴, Sophie Roux⁴, Gilles Boire⁵ and Ariel Masetto⁴, ¹Université de Sherbrooke, Division of Rheumatology, Department of Medicine and Health Sciences, Sherbrooke, Canada, and Centre intégré universitaire de santé et de services sociaux de l’Estrie – Centre hospitalier universitaire de Sherbrooke (CIUSSS de l’Estrie – CHUS), Sherbrooke, Canada, Saint-Augustin-de-Desmaures, QC, Canada, ²Centre integré universitaire de santé et de services sociaux de l’Estrie – Centre hospitalier universitaire de Sherbrooke (CIUSSS de l’Estrie-CHUS), Sherbrooke, Canada, ³Université de Sherbrooke, Sherbrooke, Canada, ⁴Université de Sherbrooke, Division of Rheumatology, Department of Medicine and Health Sciences, Sherbrooke, Canada, and Centre intégré universitaire de santé et de services sociaux de l’Estrie – Centre hospitalier universitaire de Sherbrooke (CIUSSS de l’Estrie – CHUS), Sherbrooke, Canada, Sherbrooke, Canada, ⁵Retired, Sherbrooke, QC, Canada
Background/Purpose: Calcium pyrophosphate deposition disease (CPPD) is a common cause of arthropathy over the age of 60. It can also manifest as a chronic polyarticular…
Abstract Number: 2014 • ACR Convergence 2025
Efficacy and Safety of Firsekibart in Acute Gouty Arthritis Patients with eGFR < 60ml/min/1.73m2:A Post-Hoc Analysis of 24-Week Data
Yu Xue¹, Tianshu Chu², Jiankang Hu³, Wei Gou⁴, Ning Zhang⁵, Juan Li⁶, Jing Yu⁷, Rongping Li⁸, Rongbin Li⁹, Long Qian¹⁰, Xinwang Duan¹¹, Lihua Duan¹² and Hejian Zou¹, ¹Department of Rheumatology,Huashan Hospital, Fudan University, Shanghai, China, shanghai, China (People's Republic), ²Department of Rheumatology, Henan Provincial People's Hospital, Zhengzhou, China, zhengzhou, China (People's Republic), ³Department of Rheumatology, Pingxiang People's Hospital, Pingxiang,China,, Pingxiang, China (People's Republic), ⁴Department of Rheumatology, Hebei Petro ChinaCentral Hospital, Langfang, China, Langfang, China (People's Republic), ⁵Department of Rheumatology, Shengjing Hospital of China Medical University, Shenyang, China, Shengjing, China (People's Republic), ⁶The First Affiliated Hospital of Hainan Medical University, Haikou, China (People's Republic), ⁷Department of Rheumatology, The FirstAffiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, China, Shenyang, China (People's Republic), ⁸Department of Rheumatology, The First Affiliated Hospital of GannanMedical University, Ganzhou, China, Ganzhou, China (People's Republic), ⁹Department ofRheumatology, The First Hospital of Qiqihar, Qiqihar, China, Qiqihar, China (People's Republic), ¹⁰Department of Rheumatology, The Second Hopital of Anhui Medical University, Hefei, China, Hefei, China (People's Republic), ¹¹The Second Affiliated Hospital of Nanchang University, Nanchang, China (People's Republic), ¹²Department of Rheumatology, Jiangxi Provincial People's Hospital, Nanchang, China, Nanchang, China (People's Republic)
Background/Purpose: Approximately 70% of adults with gout have CKD (Chronic Kidney Disease) ≥stage 3 (i.e estimated glomerular filtration rate (eGFR) < 60ml/min/1.73m2), significantly restricts treatment…
Abstract Number: 1123 • ACR Convergence 2025
Nanoencapsulated Sirolimus plus Pegadricase (NASP) Demonstrates Long Term Efficacy and Safety in Patients with Uncontrolled Gout: Results from the 24-week Double-blind Extension of the Phase 3 DISSOLVE I Study
Alan Kivitz¹, Atul Singhal², Anand Patel³, Rehan Azeem⁴, Ben Peace⁵, Bhavisha Desai⁶ and Herbert Baraf⁷, ¹Altoona Center for Clinical Research, Duncansville, PA, ²SouthWest Arthritis Research Group, Mesquite, TX, ³Conquest Research, Winter Park, FL, USA, Winter Park, FL, ⁴Global MACD, Sobi Inc., Waltham, MA, ⁵Statistical Science, Sobi, Stockholm, Sweden, ⁶Sobi, Glastonbury, CT, ⁷The Center for Rheumatology and Bone Research, Rheumatology, Wheaton, Maryland, USA; Division of Rheumatology, The George Washington University, Washington, DC
Background/Purpose: Uncontrolled gout (UG) occurs when serum uric acid (sUA) levels remain persistently elevated despite use of oral urate-lowering therapies and can result in progressively…
Abstract Number: 2013 • ACR Convergence 2025
Efficacy and Safety of Firsekibart in Acute Gouty Arthritis Patients with Limited Treatment Options: A Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Phase III Trial
Yu Xue¹, Tianshu Chu², Jiankang Hu³, Wei Gou⁴, Ning Zhang⁵, Juan Li⁶, Jing Yu⁷, Rongping Li⁸, Rongbin Li⁹, Long Qian¹⁰, Xinwang Duan¹¹, Lihua Duan¹² and Hejian Zou¹, ¹Department of Rheumatology,Huashan Hospital, Fudan University, Shanghai, China, shanghai, China (People's Republic), ²Department of Rheumatology, Henan Provincial People's Hospital, Zhengzhou, China, zhengzhou, China (People's Republic), ³Department of Rheumatology, Pingxiang People's Hospital, Pingxiang,China,, Pingxiang, China (People's Republic), ⁴Department of Rheumatology, Hebei Petro ChinaCentral Hospital, Langfang, China, Langfang, China (People's Republic), ⁵Department of Rheumatology, Shengjing Hospital of China Medical University, Shenyang, China, Shengjing, China (People's Republic), ⁶The First Affiliated Hospital of Hainan Medical University, Haikou, China (People's Republic), ⁷Department of Rheumatology, The FirstAffiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, China, Shenyang, China (People's Republic), ⁸Department of Rheumatology, The First Affiliated Hospital of GannanMedical University, Ganzhou, China, Ganzhou, China (People's Republic), ⁹Department ofRheumatology, The First Hospital of Qiqihar, Qiqihar, China, Qiqihar, China (People's Republic), ¹⁰Department of Rheumatology, The Second Hopital of Anhui Medical University, Hefei, China, Hefei, China (People's Republic), ¹¹The Second Affiliated Hospital of Nanchang University, Nanchang, China (People's Republic), ¹²Department of Rheumatology, Jiangxi Provincial People's Hospital, Nanchang, China, Nanchang, China (People's Republic)
Background/Purpose: Acute gouty arthritis(GA) is a common and debilitating condition, especially for patients unsuitable for standard therapy. Firsekibart, previously called Genakumab, is a first-in-class fully…
Abstract Number: 1101 • ACR Convergence 2025
Distinct Clinical Phenotypes of Immune Checkpoint Inhibitor–Associated Arthritis: Comparative Analysis of Inflammatory Arthritis, Polymyalgia Rheumatica-like, Activated Crystalline, and Activated Osteoarthritis
Heba Altarawneh¹, Gregory Challener², Mazen Nasrallah³, Janeth Yinh⁴, Hyon K. Choi⁵ and Minna Kohler⁶, ¹Mass General Hospital, Boston, MA, ²MGH, Boston, MA, ³MGB-Salem Hospital, Lynn, MA, ⁴Massachusetts General Hospital, Boston, MA, ⁵MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁶Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Immune checkpoint inhibitor (ICI)–associated arthritis has been classified into distinct phenotypes, including inflammatory arthritis (IA), polymyalgia rheumatica (PMR)-like syndrome, activated crystalline arthritis, and activated…
Abstract Number: 2012 • ACR Convergence 2025
A Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of ABP-671 in Subjects with Hyperuricemia or Gout in China
ullrich schwertschlag¹, yan yang², Jingfei li³, Roy Wu⁴, adam jin² and William Shi⁵, ¹Atom Therapeutics, PALO ALTO, CA, ²Atom Therapeutics, Suzhou, China (People's Republic), ³Atom Therapeutics, Suzhou, Jiangsu, China (People's Republic), ⁴Atom Bioscience, San Francisco, CA, ⁵Atom Therapeutics, Newark, CA
Background/Purpose: ABP-671 is a novel, selective and potent URAT1 inhibitor in development for the treatment of elevated serum uric acid (sUA) levels and gout.Methods: Subjects…

1
2
3
…
8
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].